Skip to main content

Table 1 Baseline characteristics grouped by CD8 status (N=48)

From: Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Characteristics All 10-20% (n=35) > 20% (n=13)
Age, years
 Median (IQR) 50 (39-60) 49 (38-58) 52 (46-60)
 < 40 12 (25.0) 10 (28.6) 2 (15.4)
 ≥ 40 36 (75.0) 25 (71.4) 11 (84.6)
Disease status
 Metastatic, de novo 16 (33.3) 9 (25.7) 7 (53.8)
 Metastatic, recurrent 31 (64.6) 26 (74.3) 5 (38.5)
 TFI 6-12 months 15 (31.3) 12 (34.3) 3 (23.1)
 TFI >12 months 16 (33.3) 14 (37.1) 2 (15.4)
 Locally inoperable advanced 1 (2.1) 0 (0) 1 (7.7)
ECOG performance status
 0 18 (37.5) 11 (31.4) 7 (53.8)
 1 30 (62.5) 24 (68.6) 6 (46.2)
Baseline disease
 0 15 (31.2) 8 (22.9) 7 (53.8)
 1 31 (64.6) 25 (71.4) 6 (46.2)
 NA 2 (4.2) 2 (5.7) 0 (0)
Number of metastatic sites
 < 3 25 (52.1) 18 (51.4) 7 (53.8)
 ≥ 3 23 (47.9) 17 (48.6) 6 (46.2)
Metastatic site
 Lung 24 (50.0) 19 (54.3) 5 (38.5)
 Liver 10 (20.8) 8 (22.9) 2 (15.4)
 Bone 19 (39.6) 16 (45.7) 3 (23.1)
Neo/adjuvant chemotherapy
 Any 32 (66.7) 26 (74.3) 6 (46.2)
 Anthracycline 30 (62.5) 24 (68.6) 6 (46.2)
 Taxane 29 (60.4) 23 (65.7) 6 (46.2)
 Platinum 6 (12.5) 6 (17.1) 0 (0)
 Capecitabine 5 (10.4) 3 (8.6) 2 (15.4)
PD-L1 status
 Positive 17 (35.4) 9 (25.7) 8 (61.5)
 Negative 13 (27.1) 10 (28.6) 3 (23.1)
 Unknown 18 (37.5) 16 (45.7) 2 (15.4)
  1. Data are presented as No. (%) unless otherwise indicated
  2. Abbreviation: ECOG Eastern Cooperative Oncology Group, TFI treatment-free interval, PD-L1 programmed death-ligand 1